

June 15, 2021



# Sutro Biopharma to Participate in Two Virtual Investor Conferences in June

SOUTH SAN FRANCISCO, Calif., June 15, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will participate in two virtual investor conferences in June.

## Presentation Details

### **JMP Securities Life Sciences Conference**

Format: Fireside Chat

Date: Thursday, June 17, 2021

Time: 3:30 p.m. ET / 12:30 p.m. PT

### **Raymond James Human Health Innovations Conference**

Format: Panel Session

Panel Title: Targeted Oncology 2: Antibody Drug Conjugates

Date: Wednesday, June 23, 2021

Time: 10:40 a.m. ET / 7:40 a.m. PT

Live webcasts of each presentation can be accessed through the Events and Presentations page of the Investor Relations section on the company's website at [www.sutrobio.com](http://www.sutrobio.com). Archived replays of the webcasts will be available on the company's website for approximately 30 days following each live presentation.

## **About Sutro Biopharma**

Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

Sutro's proprietary and integrated cell-free protein synthesis platform XpressCF<sup>®</sup> and site-specific conjugation platform XpressCF+<sup>™</sup> led to the discovery of STRO-001 and STRO-002, Sutro's first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently being investigated in a Phase 1 clinical trial of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma. STRO-001 was granted Orphan Drug Designation by the FDA for multiple myeloma in October 2018. STRO-002 is a folate receptor alpha (FolR $\alpha$ )-targeting ADC, currently being investigated in a Phase 1 clinical trial of patients with ovarian and endometrial cancers. A third product candidate, CC-99712 (BCMA-targeting ADC), which is part of Sutro's collaboration with Bristol Myers Squibb (formerly Celgene Corporation), is enrolling patients for its Phase 1 clinical trial of patients with multiple myeloma and has received Orphan Drug Designation from the FDA for multiple myeloma. A fourth product candidate, M1231, (MUC1-EGFR, first-in-class bispecific

ADC), which is part of Sutro's collaboration with Merck KGaA, EMD Serono (EMD Serono) is enrolling patients for its Phase 1 clinical trial of patients with metastatic solid tumors, non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma. The four product candidates above being evaluated in clinical trials resulted from Sutro's XpressCF<sup>®</sup> and XpressCF+<sup>™</sup> technology platforms. Bristol Myers Squibb and EMD Serono have worldwide development and commercialization rights for CC-99712 and M1231, respectively, for which Sutro is entitled to milestone or contingent payments and tiered royalties.

Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro's platform has led to cytokine-based immuno-oncology therapies, ADCs, vaccines and bispecific antibodies directed at precedented targets in clinical indications where the current standard of care is suboptimal.

The platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.

In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics. As the pace of clinical development accelerates, Sutro and its partners are developing therapeutics designed to more efficiently kill tumors without harming healthy cells.

Follow Sutro on Twitter, [@SutroBio](#), and at [www.sutro.bio.com](http://www.sutro.bio.com) to learn more about our passion for changing the future of oncology.

#### **Investor Contacts**

Annie J. Chang  
Sutro Biopharma  
(650) 801-5728  
[ajchang@sutro.bio.com](mailto:ajchang@sutro.bio.com)

#### **Media Contacts**

Maggie Beller  
Russo Partners  
(646) 942-5631  
[Maggie.beller@russopartnersllc.com](mailto:Maggie.beller@russopartnersllc.com)

View original content: <http://www.prnewswire.com/news-releases/sutro-biopharma-to-participate-in-two-virtual-investor-conferences-in-june-301312357.html>

SOURCE Sutro Biopharma